Tafoxiparin is protected by several patent families

Dilafor´s drug product candidate tafoxiparin, is protected by several patent families with basic patent expiries in 2023-2034. Substance patent protection for tafoxiparin has been granted worldwide, with just a few countries remaining to be granted due to slower patent examination procedures. Further patent applications are also on file, covering additional aspects of Dilafor´s development programme.


As many as 40% of all pregnant women experience protracted labor, which carries a high risk of complications for both mothers and infants.